Home>Topics>Stocks>NPS Pharmaceuticals

NPS Pharmaceuticals NPSP

  1. All
  2. Commentary
  3. Headlines
    1. Shire Reports Solid 1Q on Strong Vyvanse sales; Increasing FVE Modestly

      Commentary

      Thu, 30 Apr 2015

      continue to think the company's growth by acquisition strategy, such as its recent $5.2 billion purchase of NPS Pharmaceuticals reinforces Shire's narrow economic moat, as the deal adds new drugs to its growing rare disease portfolio and

    2. Shire Fourth Quarter In-Line; Guidance a Bit Soft due to Currency Impacts; Shares Fairly Valued

      Commentary

      Thu, 12 Feb 2015

      impacts. We think the company's growth by acquisition strategy, such as its recent $5.2 billion purchase of NPS Pharmaceuticals , reinforces Shire's narrow economic moat, as the deal adds new drugs to its growing rare disease portfolio

    3. Shire shares jump as drug approval vindicates $5.2 bln NPS purchase

      Headlines

      Mon, 26 Jan 2015

      LONDON, Jan 26 (Reuters) - Shire Plc shares gained more than 3 percent on Monday following news U.S. regulators had approved NPS Pharmaceuticals Inc's drug Natpara, validating Shire's decision to buy...

    4. Rise in healthcare stocks lifts European equities

      Headlines

      Mon, 12 Jan 2015

      LONDON, Jan 12 (Reuters) - A rise in healthcare shares, following renewed signs of industry consolidation after Shire Plc agreed to buy NPS Pharmaceuticals for $5.2 billion, lifted European equities...

    5. Shire’s Acquisition of NPS Pharma Adds to its Moaty Rare Disease Portfolio; Increasing FVE Modestly

      Commentary

      Sun, 11 Jan 2015

      We anticipate increasing Shire’s FVE by about 5% following its agreement to acquire NPS Pharmaceuticals for $5.2 billion in cash (or $46 per share). We think it reinforces Shire's narrow economic moat, as the deal will add

    6. Deals of the day- Mergers and acquisitions

      Headlines

      Mon, 5 Jan 2015

      (Adds NPS Pharmaceuticals , Revel Casino Hotel, Bang & Olufsen, Energy Fuels)

    7. FDA extends review date for NPS Pharma hormone replacement therapy

      Headlines

      Thu, 23 Oct 2014

      Oct 23 (Reuters) - NPS Pharmaceuticals Inc said the U.S. Food and Drug Administration had extended the review date for its hormone replacement therapy by three months to provide time for a full...

    8. Five Things You Should Know About U.S. Small-Caps

      Headlines

      Mon, 20 Oct 2014

      NPS Pharmaceuticals NPSP raised $50 million Monday through the sale of its Preotact royalty stream to Drug Royalty Corporation. We're maintaining our

    9. Sell-Off in Health Care Sector Overlooks Strong Fundamentals

      Headlines

      Fri, 25 Apr 2014

      Pharmaceuticals International, Inc. (U.S. Shares) (2.19%), AstraZeneca PLC (ADR) (1.78%) and NPS Pharmaceuticals , Inc. (1.74%). There are no assurances that any Janus portfolio currently holds these securities or other

    10. FDA staff says NPS Pharma's bowel drug needs no safety restrictions

      Headlines

      Fri, 12 Oct 2012

      (Reuters) - U.S. drug reviewers found three serious concerns related to NPS Pharmaceuticals Inc's experimental drug for short bowel syndrome but said they did not think the drug needed to be...

    « Prev123Next »
    Content Partners